Literature DB >> 16760013

Ileal carcinoid tumor with liver metastases and cardiac involvement treated with intraarterial liposomal doxorubicin and valve replacement.

M González Cao1, G Bastarrika, J García-Foncillas, J Aristu, A Chopitea, S Martín Algarra.   

Abstract

Unless carcinoid are in general slow-growing tumors, some cases could be frankly malignant. The commonest cause of death in patients suffering a carcinoid tumor is liver failure due to tumor progression. When tumors have a fast evolution a multidisciplinary approach must be perform. This case report is an example of this specific situation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16760013     DOI： 10.1007/s12094-006-0184-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  10 in total

1.  The classification of carcinoid tum ours.

Authors:  E D WILLIAMS; M SANDLER
Journal:  Lancet       Date:  1963-02-02       Impact factor: 79.321

Review 2.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

3.  Acute doxorubicin cardiotoxicity.

Authors:  Emil R Hayek; Eric Speakman; Esther Rehmus
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin.

Authors:  O Cay; J B Kruskal; I Nasser; P Thomas; M E Clouse
Journal:  Radiology       Date:  1997-10       Impact factor: 11.105

Review 5.  Carcinoid tumour.

Authors:  M E Caplin; J R Buscombe; A J Hilson; A L Jones; A F Watkinson; A K Burroughs
Journal:  Lancet       Date:  1998-09-05       Impact factor: 79.321

6.  Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors.

Authors:  Alain Roche; Baragur V Girish; Thierry de Baère; Eric Baudin; Valérie Boige; Dominique Elias; Philippe Lasser; Martin Schlumberger; Michel Ducreux
Journal:  Eur Radiol       Date:  2002-07-23       Impact factor: 5.315

7.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Carcinoid case presentation and discussion: the American perspective.

Authors:  R R P Warner
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

Review 9.  Management of neuroendocrine liver metastases.

Authors:  Robert Sutcliffe; Donal Maguire; John Ramage; Mohamed Rela; Nigel Heaton
Journal:  Am J Surg       Date:  2004-01       Impact factor: 2.565

10.  Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.

Authors:  M B Jacobsen; L E Hanssen; F Kolmannskog; E Schrumpf; M H Vatn; A Bergan
Journal:  Scand J Gastroenterol       Date:  1995-08       Impact factor: 2.423
  10 in total
  1 in total

Review 1.  Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review.

Authors:  Alexander Massmann; Thomas Rodt; Steffen Marquardt; Roland Seidel; Katrina Thomas; Frank Wacker; Götz M Richter; Hans U Kauczor; Arno Bücker; Philippe L Pereira; Christof M Sommer
Journal:  Langenbecks Arch Surg       Date:  2015-06-19       Impact factor: 3.445
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.